Sucampo Pharmaceuticals 10-Q 6 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Sucampo Pharmaceuticals, Inc.
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		45,155,885
Amendment Flag	FALSE
Entity Central Index Key	1365216
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$59,639	$71,622
Investments, current	33,232	22,393
Product royalties receivable	15,746	18,576
Accounts receivable, net	8,153	5,338
Deferred tax assets, current	382	476
Deferred charge, current	295	295
Restricted cash, current	213	213
Inventory	328
Prepaid expenses and other current assets	2,865	3,411
Total current assets	120,853	122,324
Investments, non-current	23,410	13,540
Property and equipment, net	634	763
Intangible assets, net	146	151
Deferred tax assets, non-current	612	571
Deferred charge, non-current	1,621	1,695
Restricted cash, non-current	2,282	2,224
Other assets	251	306
Total assets	149,809	141,574
Current liabilities:
Accounts payable	1,411	4,143
Accrued expenses	9,658	8,467
Deferred revenue, current	1,771	2,051
Collaboration obligation	5,939	6,000
Income tax payable	1,847	1,291
Notes payable, current	8,240	8,240
Other current liabilities	1,832	3,618
Total current liabilities	30,698	33,810
Notes payable, non-current	17,578	17,578
Deferred revenue, non-current	4,889	5,118
Deferred tax liability, non-current	654	820
Other liabilities	1,957	1,936
Total liabilities	55,776	59,262
Stockholders' equity:
Preferred stock, $0.01 par value; 5,000,000 shares authorized at March 31, 2015 and December 31, 2014; no shares issued and outstanding at March 31, 2015 and December 31, 2014	0	0
Additional paid-in capital	88,792	83,646
Accumulated other comprehensive income	14,427	14,265
Treasury stock, at cost; 524,792 shares at March 31, 2015 and December 31, 2014	-2,313	-2,313
Accumulated deficit	-7,324	-13,732
Total stockholders' equity	94,033	82,312
Total liabilities and stockholders' equity	149,809	141,574
Common Class A [Member]
Stockholders' equity:
Common stock value	451	446
Common Class B [Member]
Stockholders' equity:
Common stock value	$0	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred stock, par value (in Dollars per share)	$0.01	$0.01
Preferred stock,shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury stock, shares	524,792	524,792
Common Class A [Member]
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	270,000,000	270,000,000
Common stock, shares issued	45,119,780	44,602,988
Common stock, shares outstanding	45,119,780	44,602,988
Common Class B [Member]
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Research and development revenue	$2,345	$1,784
Product royalty revenue	15,745	13,501
Product sales revenue	11,145	6,312
Co-promotion revenue		362
Contract and collaboration revenue	245	202
Total revenues	29,480	22,161
Costs and expenses:
Costs of goods sold	6,110	3,393
Research and development	6,793	5,135
General and administrative	6,283	7,257
Selling and marketing	640	3,647
Total costs and expenses	19,826	19,432
Income from operations	9,654	2,729
Non-operating income (expense):
Interest income	40	57
Interest expense	-276	-400
Other expense, net	-203	-323
Total non-operating expense, net	-439	-666
Income before income taxes	9,215	2,063
Income tax provision	-2,807	-1,308
Net income	6,408	755
Net income per share:
Basic (in Dollars per share)	$0.14	$0.02
Diluted (in Dollars per share)	$0.14	$0.02
Weighted average common shares outstanding:
Basic (in Shares)	44,366	43,401
Diluted (in Shares)	45,912	44,264
Comprehensive income:
Net income	6,408	755
Other comprehensive income (expense):
Unrealized loss on pension benefit obligation	-7
Unrealized gain (loss) on investments, net of tax effect	-6	7
Foreign currency translation gain (loss)	175	-118
Comprehensive income	$6,570	$644

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Changes in Stockholdersb Equity (Unaudited) (USD $)	Common Class A [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
	Common Stock [Member]
Balance at Dec. 31, 2014	$446,000	$83,646,000	$14,265,000	($2,313,000)	($13,732,000)	$82,312,000
Balance (in Shares) at Dec. 31, 2014	44,602,988			524,792
Employee stock option expense		1,069,000				1,069,000
Stock issued under exercise of stock options	5,000	3,265,000				3,270,000
Stock issued under exercise of stock options (in Shares)	515,842
Stock issued under employee stock purchase plan		11,000				11,000
Stock issued under employee stock purchase plan (in Shares)	950
Windfall tax benefit from stock-based compensation		801,000				801,000
Unrealized loss on pension benefit obligation			-7,000			-7,000
Unrealized loss on investments, net of tax effect			-6,000			-6,000
Foreign currency translation			175,000			175,000
Net income					6,408,000	6,408,000
Balance at Mar. 31, 2015	$451,000	$88,792,000	$14,427,000	($2,313,000)	($7,324,000)	$94,033,000
Balance (in Shares) at Mar. 31, 2015	45,119,780			524,792

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$6,408	$755
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	83	361
Deferred tax provision	-114	-395
Deferred charge	74	168
Stock-based compensation	1,069	228
Amortization of premiums on investments	26	26
Unrealized currency translations	18	210
Shortfall from stock-based compensation	-68
Changes in operating assets and liabilities:
Accounts receivable	-2,707	965
Unbilled accounts receivable	-112	-2
Product royalties receivable	2,830	1,328
Inventory	-328	-245
Prepaid and income taxes receivable and payable, net	556	-5
Accounts payable	-2,727	-1,630
Accrued expenses	1,200	303
Deferred revenue	-446	48
Collaboration obligation	-61
Accrued interest payable	275	359
Indirect taxes payable	-2,110	1,246
Other assets and liabilities, net	713	-159
Net cash provided by operating activities	4,579	3,561
Cash flows from investing activities:
Purchases of investments	-25,987
Proceeds from the sales of investments		1,700
Maturities of investments	5,250	250
Purchases of property and equipment	-12	-41
Net cash provided by (used in) investing activities	-20,749	1,909
Cash flows from financing activities:
Proceeds from exercise of stock options	3,270	1,116
Proceeds from employee stock purchase plan	11	5
Proceeds from "at-the-market" stock issuance		5,327
Windfall benefit from stock-based compensation	869	18
Net cash provided by financing activities	4,150	6,466
Effect of exchange rates on cash and cash equivalents	37	104
Net increase (decrease) in cash and cash equivalents	-11,983	12,040
Cash and cash equivalents at beginning of period	71,622	44,102
Cash and cash equivalents at end of period	$59,639	$56,142

Note_1_Business_Organization_a

Note 1 - Business Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1.      Business Organization and Basis of Presentation
	Description of the Business
	Sucampo Pharmaceuticals, Inc., (the Company) is a global biopharmaceutical company focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide.
	The Company is currently focused on developing compounds known as prostones, which are ion channel activators, to treat gastrointestinal and oncology-based inflammatory disorders.
	The Company currently generates revenue primarily from product royalties, development milestone payments, product sales and reimbursements for clinical development activities. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks regulatory approvals and additional indications for approved products and other compounds and seeks strategic opportunities for in-licensing non-prostone clinical candidates.
	AMITIZA® (lubiprostone) is marketed in the United States (U.S.) for three gastrointestinal indications under the collaboration and license agreement (as amended in October 2014, the North America Takeda Agreement) with Takeda Pharmaceutical Company Limited (Takeda). These indications are chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults suffering from chronic non-cancer related pain. Under the North America Takeda Agreement, the Company is primarily responsible for clinical development activities while Takeda is responsible for commercialization of AMITIZA in the U.S. and Canada. In Canada, the Company has filed a New Drug Submission (NDS) for AMITIZA for the CIC and OIC indications and anticipates a decision in the second half of 2015. In October 2014, the Company and Takeda executed amendments (Takeda Amendment) to the North America Takeda Agreement as well as to the ancillary agreements which, among other things, extended the term of the North America Takeda Agreement beyond December 2020. During the extended term, Takeda and the Company will split the annual net sales revenue of the branded AMITIZA products. In addition, the North America Takeda Agreement was amended to terminate the Company’s right to perform commercialization activities with respect to AMITIZA and Takeda’s obligation to reimburse the Company for such commercialization activities.
	In Japan, AMITIZA is marketed under a license, commercialization and supply agreement (the Japan Mylan Agreement) that was purchased by Mylan, Inc. (Mylan) from Abbott Laboratories, Inc. (Abbott), as of February 25, 2015, as part of Mylan’s acquisition of a product portfolio from Abbott. Mylan markets AMITIZA in Japan for the gastrointestinal indication of chronic constipation (CC) excluding constipation caused by organic diseases. AMITIZA is Japan’s only prescription medicine for CC. The Company does not expect any significant changes in the commercialization of AMITIZA in Japan as a result of the transfer of the Japan Mylan Agreement from Abbott to Mylan.
	In October 2014, the Company entered into an exclusive license, development, commercialization and supply agreement (the Global Takeda License Agreement) for lubiprostone with Takeda, where Takeda has the exclusive rights to further develop and commercialize AMITIZA in all global markets, except the U.S., Canada, Japan and the People’s Republic of China. In addition, Takeda will become the marketing authorization holder and will be responsible for all commercialization and regulatory activities in the areas covered by the Global License Agreement. In the United Kingdom (U.K.), Takeda markets AMITIZA for CIC and in Switzerland, CIC and OIC. The Company filed for the OIC indication in the U.K., but in March 2014 the Company received notification from the Medicines and Healthcare Products Regulatory Agency (MHRA) that the application for the OIC indication was not approved and we have since resubmitted the application for OIC for re-review to MHRA. The Company currently awaits MHRA’s decision on the OIC indication. In January 2015, the Company successfully completed the European mutual recognition procedure (MRP) for AMITIZA for the treatment of CIC in select European countries, resulting in a recommendation for marketing authorization. As a result of that recommendation, Ireland, Belgium, the Netherlands and Luxembourg have approved AMITIZA for CIC and the Company anticipates receiving approvals by Germany, Italy, Spain and Austria in the second half of 2015.
	The Company ceased marketing RESCULA® (unoprostone isopropyl) in the fourth quarter of 2014 and in February 2015, the Company alerted physicians, pharmacists and all wholesalers that after the March 2015 expiration date, there will be no further product available.
	The Company’s other clinical development programs include the following:
	Lubiprostone Alternate Formulation
	The Company is developing an alternate formulation of lubiprostone, both for adult and pediatric patients who are unable to take capsules and for naso-gastric tube fed patients. Takeda is funding 100% of the costs of this alternate formulation work and the Company expects to initiate a phase 3 trial of the alternate formulation of lubiprostone in the second half of 2015.
	Lubiprostone for Pediatric Functional Constipation
	The phase 3 program required for obtaining marketing approval of lubiprostone for pediatric functional constipation comprises of four clinical trials, two of which are currently ongoing and are both testing the soft gelatin capsule formulation of lubiprostone in patients 6 to 17 years of age. The first of the two trials is a pivotal 12-week, randomized, placebo-controlled trial which was initiated in December 2013. The second trial is a follow-on, long-term safety extension study which was initiated in March 2014. The Company is also evaluating the timing of the initiation of the additional two trials in our phase 3 program for pediatric functional constipation, which will be in children aged 6 months to less than 6 years and will require the alternate formulation of lubiprostone as described above.
	Cobiprostone for Oral Mucositis (OM)
	The Company completed its phase 1b trial that evaluated the safety and pharmacokinetics of an oral spray formulation of cobiprostone for OM. The results of this phase 1b trial showed that cobiprostone was well-tolerated overall and revealed low systemic exposure. The Company filed an Investigational New Drug (IND) application for cobiprostone to initiate a phase 2a clinical trial in patients suffering from head and neck cancer for the treatment of OM in March 2015. The clinical trial is expected to begin at the end of the first half of 2015. The Company had also filed for orphan drug designation in the E.U. but in April 2015 withdrew the application as the target population estimate is too large for the orphan drug status.
	Cobiprostone for Non-Erosive Reflux Disease (NERD)
	The Company initiated a phase 2 program for cobiprostone in NERD in patients who have had a non-satisfactory response to proton pump inhibitors at the end of 2014.
	Unoprostone Isopropyl
	In March 2015, the Company announced that it would return all licenses for unoprostone isopropyl to R-Tech Ueno, Ltd (R-Tech). These licenses had provided the Company with exclusive development and commercialization rights to unoprostone isopropyl globally except for Japan, the People’s Republic of China, Taiwan and Korea, and covered certain indications including the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, retinitis pigmentosa and geographic atrophy. On May 1, 2015, the Company and R-Tech executed a transfer and termination agreement to effectuate the return of the licenses as well as regulatory, commercial and pharmacovigilance information. As a result of this agreement, the Company will receive a payment of $2.6 million from R-Tech.
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 9, 2015. The financial information as of March 31, 2015 and for the three months ended March 31, 2015 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG (SAG) based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, LLC (SPL) based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, (SPA) based in Bethesda, Maryland, through which the Company conducts its North American operations; and Sucampo Pharma Europe, Ltd., (SPE) based in Oxford, United Kingdom. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Revisions to Previously Issued Financial Statements
	The Company has revised the Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2014 to correct errors in the recognition of indirect taxes at SAG. During that period, the Company overstated its indirect tax liability and understated net income. The Company is including herein the correction of all such immaterial errors that have not been revised in its previous periodic filings.
		Presentation as of the three months ended March 31, 2014
	Consolidated Statements of Operations and Comprehensive Income	As Previously Reported			Revision Adjustment			As Revised
	(In thousands)
	Costs of goods sold	$	3,517		$	(124	)	$	3,393
	Income from operations		2,605			124			2,729
	Income before income taxes		1,939			124			2,063
	Income tax provision		(1,264	)		(44	)		(1,308	)
	Net income		675			80			755
	Comprehensive income		564			80			644

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2.      Summary of Significant Accounting Policies
	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of March 31, 2015 and December 31, 2014, approximately $33.5 million or 28.2%, and $37.0 million or 33.6%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	Revenues from Takeda, an unrelated party, accounted for 61.8% and 71.2% of the Company’s total revenues for the three months ended March 31, 2015 and 2014, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 65.9% and 88.5% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at March 31, 2015 and December 31, 2014, respectively. Revenues from other unrelated parties, Abbott and Mylan, accounted for 37.8% and 27.5% of the Company’s total revenues for the three months ended March 31, 2015 and 2014, respectively. The Company depends significantly upon collaborations with Takeda and Mylan, and its revenues may be impacted if these relationships are disrupted.
	Inventory
	Inventory is stated at cost or market, whichever is lower. Cost is determined on a first-in, first-out basis. Inventory is reviewed periodically for potential excess, dated or obsolete status. The Company’s management evaluates the carrying value of inventory on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the prices the Company expects to obtain for products in their respective markets compared to historical costs, and the remaining shelf life of goods on hand.
	Recent Accounting Pronouncements
	There have been no recent accounting pronouncements that are expected to have a material impact on the Company's financial statements.

Note_3_Net_Income_per_Share

Note 3 - Net Income per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	3.      Net Income per Share
	Basic net income per share is computed by dividing net income by the sum of the weighted average class A common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding.
	The computation of net income per share for the three months ended March 31, 2015 and 2014 is shown below:
		Three Months Ended March 31,
	(In thousands, except per share data)	2015		2014
	Basic net income per share:
	Net income	$	6,408	$	755
	Weighted average class A common shares outstanding		44,366		43,401
	Basic net income per share	$	0.14	$	0.02
	Diluted net income per share:
	Net income	$	6,408	$	755
	Weighted average class A common shares outstanding		44,366		43,401
	Assumed exercise of stock options under the treasury stock method		1,546		863
			45,912		44,264
	Diluted net income per share	$	0.14	$	0.02
	The potentially dilutive securities used in the calculations of diluted net income per share for the three months ended March 31, 2015 and 2014 are as follows:
		Three Months Ended March 31,
	(In thousands)	2015		2014
	Employee stock options		3,649		2,663
	Non-employee stock options		-		343
	The following securities were excluded from the computation of diluted net income per share as their effect would be anti-dilutive for the three months ended March 31, 2015 and 2014:
		Three Months Ended March 31,
	(In thousands)	2015		2014
	Employee stock options		957		342

Note_4_Current_and_NonCurrent_

Note 4 - Current and Non-Current Investments	3 Months Ended
	Mar. 31, 2015
Investments Schedule [Abstract]
Investment [Text Block]	4.      Current and Non-Current Investments
	At March 31, 2015 and December 31, 2014, current and non-current available-for-sale investments consisted of the following securities:
		31-Mar-15
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	Certificates of deposit	$	5,250	$	-	$	-		$	5,250
	Commercial paper		13,517		-		-			13,517
	Corporate bonds		10,789		-		(1	)		10,788
	U.S. government agencies		3,178		-		-			3,178
	U.S. treasury bills and notes		499		-		-			499
	Total	$	33,233	$	-	$	(1	)	$	33,232
	Non-current:
	Certificates of deposit	$	6,500	$	-	$	-		$	6,500
	U.S. government agencies		16,910		-		-			16,910
	Total	$	23,410	$	-	$	-		$	23,410
		31-Dec-14
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	4,203	$	1	$	-		$	4,204
	Certificates of deposit		2,500		-		-			2,500
	Corporate bonds		4,575		-		(3	)		4,572
	U.S. commercial paper		11,109		8		-			11,117
	Total	$	22,387	$	9	$	(3	)	$	22,393
	Non-current:
	U.S. government agencies	$	8,047	$	-	$	(15	)	$	8,032
	Certificates of deposits		5,000							5,000
	Corporate bonds		509		-		(1	)		508
	Total	$	13,556	$	-	$	(16	)	$	13,540
	The Company performs fair value measurements in accordance with the Financial Accounting Standards Board’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:
	Level 1: quoted prices in active markets for identical assets or liabilities;
	Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s assets measured at fair value on a recurring basis, including cash equivalents, which are subject to the fair value disclosure requirements, are as follows:
		Fair Value Measurements at Reporting Date Using
	31-Mar-15	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs			Total
	(In thousands)	(Level 1)		(Level 2)		(Level 3)
	Certificates of deposit	$	-	$	8,772	$	-		$	8,772
	Commercial paper		-		13,517		-			13,517
	Corporate bonds		-		10,788		-			10,788
	Money market funds		10,285		-		-			10,285
	U.S. government agencies		-		20,088		-			20,088
	U.S. treasury bills and notes		-		499		-			499
	Total assets measured at fair value (a)	$	10,285	$	53,664	$	-		$	63,949
	(a) includes approximately $7.3 million of cash equivalents
		Fair Value Measurements at Reporting Date Using
	31-Dec-14	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs			Total
	(In thousands)	(Level 1)		(Level 2)		(Level 3)
	U.S. government securities	$	-	$	14,850	$	-		$	14,850
	U.S. government agencies		-		12,686		-			12,686
	U.S. commercial paper		-		15,092		-			15,092
	Certificates of deposit		-		8,000		-			8,000
	Corporate bonds		-		10,181		-			10,181
	Money market funds		3,111		-		-			3,111
	Total assets measured at fair value (b)	$	3,111	$	60,809	$	-		$	63,920
	(b) includes approximately $28.0 million of cash equivalents
	If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.

Note_5_Inventory

Note 5 - Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5.      Inventory
	As of March 31, 2015, inventory consisted of product held under the Global Takeda License Agreement.

Note_6_Accrued_Expenses_and_Ot

Note 6 - Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6.      Accrued Expenses and Other Current Liabilities
	Accrued expenses consisted of the following at March 31, 2015 and December 31, 2014:
	(In thousands)	March 31,		December 31,
		2015		2014
	Research and development costs	$	2,851	$	2,409
	Commercial supplies		3,284		1,128
	Employee compensation		2,095		3,459
	Selling and marketing costs		183		163
	Legal service fees		472		612
	Other accrued expenses		773		696
	Total	$	9,658	$	8,467
	Other current liabilities consisted of the following at March 31, 2015 and December 31, 2014:
	(In thousands)	March 31,		December 31,
		2015		2014
	Indirect taxes payable	$	1,013	$	3,075
	Other liabilities		819		543
	Total	$	1,832	$	3,618

Note_7_Commitments_and_Conting

Note 7 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	7.     Commitments and Contingencies
	Operating Leases
	The Company leases office space in the United States, Switzerland and Japan under operating leases through 2018. Total future minimum, non-cancelable lease payments under operating leases are as follows:
	(In thousands of U.S. dollars)	March 31,
		2015
	2015	$	1,006
	2016		1,191
	2017		156
	2018		8
	Total minimum lease payments	$	2,361
	Rent expense for all operating leases was approximately $333,000 and $454,000 for the three months ended March 31, 2015 and March 31, 2014, respectively.
	Research and Development Costs
	The Company routinely enters into agreements with third-party contract research organizations to oversee clinical research and development studies provided on an outsourced basis, and to assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. Total future estimated costs under these agreements as of March 31, 2015 were approximately $7.6 million.
	Numab Commitment
	In the event that Numab defaults under its loan with Zurcher Kantonalbank, the Company’s maximum contingent liability under the Numab Agreement (see Note 8 below) is $2.3 million. As of March 31, 2015, the potential amount of payments in the event of Numab’s default was $2.1 million. At March 31, 2015 the Company had a recorded liability of $1.0 million in collateral callable to meet a potential loan default by Numab.
	Legal Proceedings
	See Item 1. Legal Proceedings in Part II OTHER INFORMATION included elsewhere in this Quarterly Report on Form 10-Q.

Note_8_Related_Party_Transacti

Note 8 - Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	8.      Related Party Transactions
	R-Tech Ueno, Ltd.
	The Company recorded the following expenses under all of its agreements with R-Tech, including the April 2009 license agreement with R-Tech for unoprostone isopropyl in the U.S. and Canada and March 2011 agreement with R-Tech for unoprostone isopropyl in the rest of the world other than U.S. Canada, Japan, South Korea, Taiwan and China and various exclusive supply agreements with R-Tech:
		Three Months Ended March 31,
	(In thousands)	2015		2014
	Clinical supplies	$	31	$	101
	Other research and development services		5		10
	Commercial supplies		6,142		3,547
		$	6,178	$	3,658
	The following table summarizes the amounts included in deferred revenue resulting from the deferral of upfront payments relating to the exclusive supply agreements with R-Tech:
	(In thousands)	March 31,		December 31,
		2015		2014
	Deferred revenue, current	$	138	$	453
	Deferred revenue, non-current		4,240		4,141
		$	4,378	$	4,594
	The Company recognized approximately $138,000 and $164,000 of revenue relating to its agreements with R-Tech for the three months ended March 31, 2015 and 2014, respectively, which was recorded as contract and collaboration revenue in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income.
	Drs. Ryuji Ueno and Sachiko Kuno are married to each other and, directly or indirectly, owned a majority of the stock of R-Tech through March 31, 2015. Subsequently, through a public marketed offering in Japan, they reduced their ownership in R-Tech below 50.0%. Drs. Ueno and Kuno have also reduced their ownership in the Company to 46.7% through a registered resale on Form S-3, and are no longer controlling stockholders of the Company as of March 31, 2015.
	Numab AG
	In September 2011, the Company entered into a Loan Guarantee and Development Agreement (Numab Agreement) with Numab. Numab is a related party of the Company as a result of the Company hiring as an executive officer an individual who holds an ownership interest in Numab. Under the terms of the Numab Agreement, the Company provided Numab with collateral and serves as guarantor for Numab on a loan from a third party, Zurcher Kantonalbank (see Note 7 above).

Note_9_Notes_Payable

Note 9 - Notes Payable	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	9.      Notes Payable
	In connection with the Company’s acquisition of SAG in December 2010, the Company issued a subordinated unsecured promissory note to each of the Ueno Trust and the Kuno Trust (the Notes). The interest rate on the Notes beginning December 1, 2014 is 4.3%. Due to changes in LIBOR rates, the Company has estimated the fair value of the notes payable as shown in the table below.
	Notes payable at their fair value and carrying value consist of the following:
		Fair Value				Carrying Value
	(In thousands)	March 31,		December 31,		March 31,		December 31,
		2015		2014		2015		2014
	Promissory notes, Sellers of SAG	$	26,317	$	26,317	$	25,818	$	25,818
	Notes payable, current					$	8,240	$	8,240
	Notes payable, non-current						17,578		17,578
						$	25,818	$	25,818
	The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 above, and is classified as a Level 2 security.

Note_10_Collaboration_Obligati

Note 10 - Collaboration Obligation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	10.   Collaboration Obligation
	Under the Global Takeda License Agreement, the Company received an upfront payment from Takeda of $14.0 million in 2014, of which the Company is obligated to reimburse Takeda for the first $6.0 million in developmental expenses incurred by Takeda. The obligation as of March 31, 2015 totaled $5.9 million.

Note_11_Collaboration_and_Lice

Note 11 - Collaboration and License Agreements	3 Months Ended
	Mar. 31, 2015
Collaborative And License Arrangement Disclosure [Abstract]
Collaborative And License Arrangement Disclosure [Text Block]	11.   Collaboration and License Agreements
	North America Takeda Agreement
	The following table summarizes the cash streams and related revenue recognized or deferred under the North America Takeda Agreement for the three months ended March 31, 2015:
	(In thousands)	Amount Deferred at December 31,		Cash Received for the Three Months Ended March 31,		Revenue Recognized for the Three Months Ended March 31,		Change in Accounts Receivable for the Three Months Ended March 31,			Amount Deferred at March 31,
		2014		2015		2015		2015*			2015
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	882	$	-	$	37	$	-		$	845
	Research and development revenue:
	Reimbursement of research and development expenses	$	-	$	1,801	$	2,345	$	1,483		$	-
	Product royalty revenue	$	-	$	18,576	$	15,745	$	(2,831	)	$	-
	Co-promotion revenue	$	-	$	1,338	$	-	$	-		$	-
	*      Includes billed and unbilled accounts receivable.
	Global Takeda License Agreement
	Product sales to Takeda under the Global Takeda License Agreement for the three months ended March 31, 2015 were approximately $8,000.
	Japan Mylan Agreement
	The following table summarizes the cash streams and related revenue recognized or deferred under the Japan Mylan Agreement for the three months ended March 31, 2015:
	(In thousands)	Amount Deferred at December 31,		Cash Received for the Three Months Ended March 31,		Revenue Recognized for the Three Months Ended March 31,		Change in Accounts Receivable for the Three Months Ended March 31,			Foreign Currency Effects for the Three Months Ended March 31,		Amount Deferred at March 31,
		2014		2015		2015		2015			2015		2015
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	453	$	-	$	30	$	-		$	-	$	423
	Product sales revenue	$	-	$	7,699	$	11,120	$	3,136		$	285	$	-

Note_12_Stock_Option_Plans

Note 12 - Stock Option Plans	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	12.      Stock Option Plans
	A summary of employee stock option activity for the three months ended March 31, 2015 under the Company’s Amended and Restated 2001 Stock Incentive Plan (the 2001 Stock Incentive Plan) is presented below:
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2014		113,900		$	10
	Options exercised		(42,500	)		10
	Options outstanding, March 31, 2015		71,400			10		1.09	$	396,984
	Options exercisable, March 31, 2015		71,400			10		1.09	$	396,984
	A summary of non-employee stock option activity for the three months ended March 31, 2015 under the 2001 Stock Incentive Plan is presented below:
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2014		255,000		$	5.85
	Options exercised		(127,500	)		5.85
	Options expired		(127,500	)		5.85
	Options outstanding, March 31, 2015		-			-		-	$	-
	Options exercisable, March 31, 2015		-			-		-	$	-
	A summary of employee stock option activity for the three months ended March 31, 2015 under the Company’s Amended and Restated 2006 Stock Incentive Plan is presented below:
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2014		4,021,491		$	6.93
	Options granted		925,200			14.49
	Options exercised		(345,842	)		6.1
	Options forfeited		(63,038	)		6.48
	Options expired		(3,434	)		4.17
	Options outstanding, March 31, 2015		4,534,377			8.54		8.88	$	31,824,902
	Options exercisable, March 31, 2015		1,141,740			5.84		6.68	$	11,098,403
	The weighted average grant date fair value of options granted during the three months ended March 31, 2015 and the year ended December 31, 2014 was $14.49 and $7.68, respectively. As of March 31, 2015, approximately $12.0 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested awards are expected to be recognized over a weighted average period of 3.49 years.
	Employee Stock Purchase Plan
	Under the Company’s 2006 Employee Stock Purchase Plan, the Company received $11,483 and $5,386 upon employees’ purchase of 950 and 793 shares of class A common stock during the three months ended March 31, 2015 and 2014, respectively.

Note_13_Pension_Expense

Note 13 - Pension Expense	3 Months Ended
	Mar. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	13.      Pension Expense
	Pension expenses relate to defined benefit pension plans for employees at SAG, the Company’s subsidiary in Switzerland (the Swiss Plan). The Swiss Plan is a government-mandated retirement fund that provides employees with a minimum investment return. The net periodic pension cost for the Swiss Plan included the following components for the three months ended March 31, 2015 and 2014:
		Three Months Ended March 31,
	(In thousands)	2015			2014
	Service cost		47			48
	Interest cost		7			11
	Expected return on assets		(10	)		(8	)
	Amortization of unrecognized net loss		18			4
	Net periodic pension cost		62			55

Note_14_Income_Taxes

Note 14 - Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14.      Income Taxes
	For the three months ended March 31, 2015 and 2014, the Company recorded tax provisions of $2.8 million and $1.3 million, respectively. The tax provision for the three months ended March 31, 2015 primarily pertained to pre-tax profits generated by the Company’s U.S, Japanese and Swiss subsidiaries and the Company’s U.S. subsidiary for the three months ended March 31, 2014.
	Uncertain Tax Positions
	The Company had an outstanding income tax liability of approximately $887,000, including interest, for uncertain tax positions as of March 31, 2015. The amount represents the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Condensed Consolidated Financial Statements. As of March 31, 2015, $887,000 is reflected as other current liabilities and other liabilities in the accompanying Condensed Consolidated Balance Sheets. The liability for uncertain tax positions as of March 31, 2015 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes. The liability for income taxes increased by approximately $45,000 due primarily to the filing positions taken in various jurisdictions related to state income tax nexus.

Note_15_Segment_Reporting

Note 15 - Segment Reporting	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	15.           Segment Reporting
	The Company made a number of strategic and operational changes to its business, including re-evaluating and accelerating its pipeline to focus on clinical programs that it believes hold the most promise for patients, the highest likelihood for regulatory approval, and the strongest potential for commercial return. As a result of such changes, in the first quarter of 2015 the Company combined its reportable geographic segments of Asia, the Americas and Europe into one operating segment which is the development and commercialization of pharmaceutical products. This change reflects the manner in which information is now being presented internally and used by the Company’s chief operating decision maker, the Company’s CEO, to allocate resources and assess performance.

Note_16_Subsequent_Events

Note 16 - Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16. Subsequent Events
	On April 22, 2015, Drs. Ueno and Kuno, individually or through S&R Technology Holdings, LLC (S&R Technology), are no longer controlling stockholders of R-Tech as they completed an underwritten public offering to reduce their ownership in R-Tech to below 50.0%.
	On May 1, 2015, the Company and R-Tech executed a transfer and termination agreement to effectuate the return of the unoprostone isopropyl licenses as well as related regulatory, commercial and pharmacovigilance information. As a result of this agreement, the Company will receive a payment of $2.6 million from R-Tech.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 9, 2015. The financial information as of March 31, 2015 and for the three months ended March 31, 2015 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG (SAG) based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, LLC (SPL) based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, (SPA) based in Bethesda, Maryland, through which the Company conducts its North American operations; and Sucampo Pharma Europe, Ltd., (SPE) based in Oxford, United Kingdom. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Error Corrections and Prior Period Adjustments, Policy [Policy Text Block]	Revisions to Previously Issued Financial Statements
	The Company has revised the Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2014 to correct errors in the recognition of indirect taxes at SAG. During that period, the Company overstated its indirect tax liability and understated net income. The Company is including herein the correction of all such immaterial errors that have not been revised in its previous periodic filings.
		Presentation as of the three months ended March 31, 2014
	Consolidated Statements of Operations and Comprehensive Income	As Previously Reported			Revision Adjustment			As Revised
	(In thousands)
	Costs of goods sold	$	3,517		$	(124	)	$	3,393
	Income from operations		2,605			124			2,729
	Income before income taxes		1,939			124			2,063
	Income tax provision		(1,264	)		(44	)		(1,308	)
	Net income		675			80			755
	Comprehensive income		564			80			644
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of March 31, 2015 and December 31, 2014, approximately $33.5 million or 28.2%, and $37.0 million or 33.6%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	Revenues from Takeda, an unrelated party, accounted for 61.8% and 71.2% of the Company’s total revenues for the three months ended March 31, 2015 and 2014, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 65.9% and 88.5% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at March 31, 2015 and December 31, 2014, respectively. Revenues from other unrelated parties, Abbott and Mylan, accounted for 37.8% and 27.5% of the Company’s total revenues for the three months ended March 31, 2015 and 2014, respectively. The Company depends significantly upon collaborations with Takeda and Mylan, and its revenues may be impacted if these relationships are disrupted.
Inventory, Policy [Policy Text Block]	Inventory
	Inventory is stated at cost or market, whichever is lower. Cost is determined on a first-in, first-out basis. Inventory is reviewed periodically for potential excess, dated or obsolete status. The Company’s management evaluates the carrying value of inventory on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the prices the Company expects to obtain for products in their respective markets compared to historical costs, and the remaining shelf life of goods on hand.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	There have been no recent accounting pronouncements that are expected to have a material impact on the Company's financial statements.

Note_1_Business_Organization_a1

Note 1 - Business Organization and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]		Presentation as of the three months ended March 31, 2014
	Consolidated Statements of Operations and Comprehensive Income	As Previously Reported			Revision Adjustment			As Revised
	(In thousands)
	Costs of goods sold	$	3,517		$	(124	)	$	3,393
	Income from operations		2,605			124			2,729
	Income before income taxes		1,939			124			2,063
	Income tax provision		(1,264	)		(44	)		(1,308	)
	Net income		675			80			755
	Comprehensive income		564			80			644

Note_3_Net_Income_per_Share_Ta

Note 3 - Net Income per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		Three Months Ended March 31,
	(In thousands, except per share data)	2015		2014
	Basic net income per share:
	Net income	$	6,408	$	755
	Weighted average class A common shares outstanding		44,366		43,401
	Basic net income per share	$	0.14	$	0.02
	Diluted net income per share:
	Net income	$	6,408	$	755
	Weighted average class A common shares outstanding		44,366		43,401
	Assumed exercise of stock options under the treasury stock method		1,546		863
			45,912		44,264
	Diluted net income per share	$	0.14	$	0.02
Schedule of Potentially Dilutive Securities [Table Text Block]		Three Months Ended March 31,
	(In thousands)	2015		2014
	Employee stock options		3,649		2,663
	Non-employee stock options		-		343
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		Three Months Ended March 31,
	(In thousands)	2015		2014
	Employee stock options		957		342

Note_4_Current_and_NonCurrent_1

Note 4 - Current and Non-Current Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Investments Schedule [Abstract]
Available-for-sale Securities [Table Text Block]		31-Mar-15
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	Certificates of deposit	$	5,250	$	-	$	-		$	5,250
	Commercial paper		13,517		-		-			13,517
	Corporate bonds		10,789		-		(1	)		10,788
	U.S. government agencies		3,178		-		-			3,178
	U.S. treasury bills and notes		499		-		-			499
	Total	$	33,233	$	-	$	(1	)	$	33,232
	Non-current:
	Certificates of deposit	$	6,500	$	-	$	-		$	6,500
	U.S. government agencies		16,910		-		-			16,910
	Total	$	23,410	$	-	$	-		$	23,410
		31-Dec-14
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	4,203	$	1	$	-		$	4,204
	Certificates of deposit		2,500		-		-			2,500
	Corporate bonds		4,575		-		(3	)		4,572
	U.S. commercial paper		11,109		8		-			11,117
	Total	$	22,387	$	9	$	(3	)	$	22,393
	Non-current:
	U.S. government agencies	$	8,047	$	-	$	(15	)	$	8,032
	Certificates of deposits		5,000							5,000
	Corporate bonds		509		-		(1	)		508
	Total	$	13,556	$	-	$	(16	)	$	13,540
Fair Value, Assets Measured on Recurring Basis [Table Text Block]		Fair Value Measurements at Reporting Date Using
	31-Mar-15	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs			Total
	(In thousands)	(Level 1)		(Level 2)		(Level 3)
	Certificates of deposit	$	-	$	8,772	$	-		$	8,772
	Commercial paper		-		13,517		-			13,517
	Corporate bonds		-		10,788		-			10,788
	Money market funds		10,285		-		-			10,285
	U.S. government agencies		-		20,088		-			20,088
	U.S. treasury bills and notes		-		499		-			499
	Total assets measured at fair value (a)	$	10,285	$	53,664	$	-		$	63,949
		Fair Value Measurements at Reporting Date Using
	31-Dec-14	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs			Total
	(In thousands)	(Level 1)		(Level 2)		(Level 3)
	U.S. government securities	$	-	$	14,850	$	-		$	14,850
	U.S. government agencies		-		12,686		-			12,686
	U.S. commercial paper		-		15,092		-			15,092
	Certificates of deposit		-		8,000		-			8,000
	Corporate bonds		-		10,181		-			10,181
	Money market funds		3,111		-		-			3,111
	Total assets measured at fair value (b)	$	3,111	$	60,809	$	-		$	63,920

Note_6_Accrued_Expenses_and_Ot1

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	(In thousands)	March 31,		December 31,
		2015		2014
	Research and development costs	$	2,851	$	2,409
	Commercial supplies		3,284		1,128
	Employee compensation		2,095		3,459
	Selling and marketing costs		183		163
	Legal service fees		472		612
	Other accrued expenses		773		696
	Total	$	9,658	$	8,467
Other Current Liabilities [Table Text Block]	(In thousands)	March 31,		December 31,
		2015		2014
	Indirect taxes payable	$	1,013	$	3,075
	Other liabilities		819		543
	Total	$	1,832	$	3,618

Note_7_Commitments_and_Conting1

Note 7 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(In thousands of U.S. dollars)	March 31,
		2015
	2015	$	1,006
	2016		1,191
	2017		156
	2018		8
	Total minimum lease payments	$	2,361

Note_8_Related_Party_Transacti1

Note 8 - Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2015
Note 8 - Related Party Transactions (Tables) [Line Items]
Schedule of Related Party Transactions [Table Text Block]		Three Months Ended March 31,
	(In thousands)	2015		2014
	Clinical supplies	$	31	$	101
	Other research and development services		5		10
	Commercial supplies		6,142		3,547
		$	6,178	$	3,658
Agreements With R-Tech [Member]
Note 8 - Related Party Transactions (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	(In thousands)	March 31,		December 31,
		2015		2014
	Deferred revenue, current	$	138	$	453
	Deferred revenue, non-current		4,240		4,141
		$	4,378	$	4,594

Note_9_Notes_Payable_Tables

Note 9 - Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]		Fair Value				Carrying Value
	(In thousands)	March 31,		December 31,		March 31,		December 31,
		2015		2014		2015		2014
	Promissory notes, Sellers of SAG	$	26,317	$	26,317	$	25,818	$	25,818
	Notes payable, current					$	8,240	$	8,240
	Notes payable, non-current						17,578		17,578
						$	25,818	$	25,818

Note_11_Collaboration_and_Lice1

Note 11 - Collaboration and License Agreements (Tables)	3 Months Ended
	Mar. 31, 2015
Takeda [Member]
Note 11 - Collaboration and License Agreements (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	(In thousands)	Amount Deferred at December 31,		Cash Received for the Three Months Ended March 31,		Revenue Recognized for the Three Months Ended March 31,		Change in Accounts Receivable for the Three Months Ended March 31,			Amount Deferred at March 31,
		2014		2015		2015		2015*			2015
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	882	$	-	$	37	$	-		$	845
	Research and development revenue:
	Reimbursement of research and development expenses	$	-	$	1,801	$	2,345	$	1,483		$	-
	Product royalty revenue	$	-	$	18,576	$	15,745	$	(2,831	)	$	-
	Co-promotion revenue	$	-	$	1,338	$	-	$	-		$	-
Abbott [Member]
Note 11 - Collaboration and License Agreements (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	(In thousands)	Amount Deferred at December 31,		Cash Received for the Three Months Ended March 31,		Revenue Recognized for the Three Months Ended March 31,		Change in Accounts Receivable for the Three Months Ended March 31,			Foreign Currency Effects for the Three Months Ended March 31,		Amount Deferred at March 31,
		2014		2015		2015		2015			2015		2015
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	453	$	-	$	30	$	-		$	-	$	423
	Product sales revenue	$	-	$	7,699	$	11,120	$	3,136		$	285	$	-

Note_12_Stock_Option_Plans_Tab

Note 12 - Stock Option Plans (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2014		113,900		$	10
	Options exercised		(42,500	)		10
	Options outstanding, March 31, 2015		71,400			10		1.09	$	396,984
	Options exercisable, March 31, 2015		71,400			10		1.09	$	396,984
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2014		255,000		$	5.85
	Options exercised		(127,500	)		5.85
	Options expired		(127,500	)		5.85
	Options outstanding, March 31, 2015		-			-		-	$	-
	Options exercisable, March 31, 2015		-			-		-	$	-
		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
	Options outstanding, December 31, 2014		4,021,491		$	6.93
	Options granted		925,200			14.49
	Options exercised		(345,842	)		6.1
	Options forfeited		(63,038	)		6.48
	Options expired		(3,434	)		4.17
	Options outstanding, March 31, 2015		4,534,377			8.54		8.88	$	31,824,902
	Options exercisable, March 31, 2015		1,141,740			5.84		6.68	$	11,098,403

Note_13_Pension_Expense_Tables

Note 13 - Pension Expense (Tables)	3 Months Ended
	Mar. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Benefit Costs [Table Text Block]		Three Months Ended March 31,
	(In thousands)	2015			2014
	Service cost		47			48
	Interest cost		7			11
	Expected return on assets		(10	)		(8	)
	Amortization of unrecognized net loss		18			4
	Net periodic pension cost		62			55

Note_1_Business_Organization_a2

Note 1 - Business Organization and Basis of Presentation (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
R-Tech [Member] | Return of Licenses and Information [Member]
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Accounts Receivable, Related Parties	2.6
Takeda [Member]
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Additioinal Reformulation Costs Funded, Percentage	100.00%

Note_1_Business_Organization_a3

Note 1 - Business Organization and Basis of Presentation (Details) - Revision to Previously Issued Financial Statements (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Costs of goods sold	$6,110	$3,393
Income from operations	9,654	2,729
Income before income taxes	9,215	2,063
Income tax provision	-2,807	-1,308
Net income	6,408	755
Comprehensive income	6,570	644
Scenario, Previously Reported [Member]
Costs of goods sold		3,517
Income from operations		2,605
Income before income taxes		1,939
Income tax provision		-1,264
Net income		675
Comprehensive income		564
Restatement Adjustment [Member]
Costs of goods sold		-124
Income from operations		124
Income before income taxes		124
Income tax provision		-44
Net income		80
Comprehensive income		$80

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Cash, FDIC Insured Amount (in Dollars)	33.5		37
PercentageOfDepositWithinFederallyInsuredLimits	28.20%		33.60%
Takeda [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	61.80%	71.20%
Takeda [Member] | Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	65.90%		88.50%
Abbott and Mylan [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	37.80%	27.50%

Note_3_Net_Income_per_Share_De

Note 3 - Net Income per Share (Details) - Net Income (Loss) per Share (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Basic net income per share:
Net income (in Dollars)	$6,408	$755
Weighted average class A common shares outstanding	44,366	43,401
Assumed exercise of stock options under the treasury stock method	1,546	863
	45,912	44,264
Diluted net income per share (in Dollars per share)	$0.14	$0.02
Basic net income per share (in Dollars per share)	$0.14	$0.02

Note_3_Net_Income_per_Share_De1

Note 3 - Net Income per Share (Details) - Potentially Dilutive Securities	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Note 3 - Net Income per Share (Details) - Potentially Dilutive Securities [Line Items]
Potentially dilutive securities	1,546	863
Employee Stock Option [Member]
Note 3 - Net Income per Share (Details) - Potentially Dilutive Securities [Line Items]
Potentially dilutive securities	3,649	2,663
Non-Employee Stock Options [Member]
Note 3 - Net Income per Share (Details) - Potentially Dilutive Securities [Line Items]
Potentially dilutive securities		343

Note_3_Net_Income_per_Share_De2

Note 3 - Net Income per Share (Details) - Antidilutive Securities (Employee Stock Options [Member])	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Employee stock options	957	342

Note_4_Current_and_NonCurrent_2

Note 4 - Current and Non-Current Investments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Investments Schedule [Abstract]
Cash and Cash Equivalents, Fair Value Disclosure	$7.30	$28

Note_4_Current_and_NonCurrent_3

Note 4 - Current and Non-Current Investments (Details) - Summary of Current and Non-Current Investments (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Certificates of Deposit [Member] | Current [Member]
Current:
Cost	$5,250	$2,500
Fair value	5,250	2,500
Certificates of Deposit [Member] | Non-current [Member]
Current:
Cost	6,500	5,000
Fair value	6,500	5,000
Commercial Paper [Member] | Current [Member]
Current:
Cost	13,517	4,575
Unrealized losses		-3
Fair value	13,517	4,572
Corporate Bond Securities [Member] | Current [Member]
Current:
Cost	10,789
Unrealized losses	-1
Fair value	10,788
Corporate Bond Securities [Member] | Non-current [Member]
Current:
Cost		509
Unrealized losses		-1
Fair value		508
US Government Agencies Debt Securities [Member] | Current [Member]
Current:
Cost	3,178	11,109
Unrealized gains		8
Fair value	3,178	11,117
US Government Agencies Debt Securities [Member] | Non-current [Member]
Current:
Cost	16,910	8,047
Unrealized losses		-15
Fair value	16,910	8,032
US Treasury Securities [Member] | Current [Member]
Current:
Cost	499
Fair value	499
US Treasury and Government [Member] | Current [Member]
Current:
Cost		4,203
Unrealized gains		1
Fair value		4,204
Current [Member]
Current:
Cost	33,233	22,387
Unrealized gains		9
Unrealized losses	-1	-3
Fair value	33,232	22,393
Non-current [Member]
Current:
Cost	23,410	13,556
Unrealized losses		-16
Fair value	$23,410	$13,540

Note_4_Current_and_NonCurrent_4

Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis (USD $)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	$8,772		$8,000
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	8,772		8,000
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	13,517		15,092
Commercial Paper [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	13,517		15,092
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	10,788		10,181
Corporate Bond Securities [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	10,788		10,181
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	10,285		3,111
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	10,285		3,111
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	20,088		12,686
US Government Agencies Debt Securities [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	20,088		12,686
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	499
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	499
US Treasury and Government [Member] | Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value			14,850
US Treasury and Government [Member] | Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value			14,850
Fair Value, Inputs, Level 1 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	10,285	[1]	3,111	[2]
Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	53,664	[1]	60,809	[2]
Fair Value, Inputs, Level 3 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value		[1]		[2]
Estimate of Fair Value Measurement [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	$63,949	[1]	$63,920	[2]
[1]	includes approximately $7.3 million of cash equivalents
[2]	includes approximately $28.0 million of cash equivalents

Note_6_Accrued_Expenses_and_Ot2

Note 6 - Accrued Expenses and Other Current Liabilities (Details) - Summary of Accrued Expenses (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of Accrued Expenses [Abstract]
Research and development costs	$2,851	$2,409
Commercial supplies	3,284	1,128
Employee compensation	2,095	3,459
Selling and marketing costs	183	163
Legal service fees	472	612
Other accrued expenses	773	696
Total	$9,658	$8,467

Note_6_Accrued_Expenses_and_Ot3

Note 6 - Accrued Expenses and Other Current Liabilities (Details) - Other Current Liabilities Summary (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Other Current Liabilities Summary [Abstract]
Indirect taxes payable	$1,013	$3,075
Other liabilities	819	543
Total	$1,832	$3,618

Note_7_Commitments_and_Conting2

Note 7 - Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 7 - Commitments and Contingencies (Details) [Line Items]
Operating Leases, Rent Expense	$333,000	$454,000
Future Estimated Research and Development Costs	7,600,000
Guarantee of Indebtedness of Others [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Loss Contingency, Range of Possible Loss, Maximum	2,300,000
Loss Contingency, Estimate of Possible Loss	2,100,000
Loss Contingency Accrual, Provision	$1,000,000

Note_7_Commitments_and_Conting3

Note 7 - Commitments and Contingencies (Details) - Future Minimum, Non-Cancelable Lease Payments (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Future Minimum, Non-Cancelable Lease Payments [Abstract]
2015	$1,006
2016	1,191
2017	156
2018	8
Total minimum lease payments	$2,361

Note_8_Related_Party_Transacti2

Note 8 - Related Party Transactions (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
R-Tech [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Contracts Revenue	$138,000	$164,000
Drs. Ueno and Kuno [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Related Party, Ownership Percentage	46.70%

Note_8_Related_Party_Transacti3

Note 8 - Related Party Transactions (Details) - Expenses Under Agreements With R-Tech (R-Tech [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Related Party Transaction [Line Items]
Expenses related to R-Tech	$6,178	$3,658
Clinical Supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	31	101
Other research and development services [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	5	10
Commercial supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	$6,142	$3,547

Note_8_Related_Party_Transacti4

Note 8 - Related Party Transactions (Details) - Deferred Revenues Under the Companybs Agreements With R-Tech (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]
Deferred revenue, current	$1,771	$2,051
Deferred revenue, non-current	4,889	5,118
R-Tech [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue, current	138	453
Deferred revenue, non-current	4,240	4,141
	$4,378	$4,594

Note_9_Notes_Payable_Details

Note 9 - Notes Payable (Details) (Kuno and Ueno Trust [Member], Subordinated Unsecured Promissory Notes [Member])	Dec. 01, 2014
Kuno and Ueno Trust [Member] | Subordinated Unsecured Promissory Notes [Member]
Note 9 - Notes Payable (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.30%

Note_9_Notes_Payable_Details_N

Note 9 - Notes Payable (Details) - Notes Payable (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Carrying Value	$25,818	$25,818
Notes payable, current	8,240	8,240
Notes payable, non-current	17,578	17,578
SAG [Member]
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Fair Value	26,317	26,317
Note Payable Carrying Value	$25,818	$25,818

Note_10_Collaboration_Obligati1

Note 10 - Collaboration Obligation (Details) (Global License Agreement [Member], Takeda [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
Note 10 - Collaboration Obligation (Details) [Line Items]
Development Expenses to be Assumed		$6,000,000
Developmental Expense Reimbursement Obligation	5,900,000
Up-front Payment Arrangement [Member]
Note 10 - Collaboration Obligation (Details) [Line Items]
Deferred Revenue		$14,000,000

Note_11_Collaboration_and_Lice2

Note 11 - Collaboration and License Agreements (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 11 - Collaboration and License Agreements (Details) [Line Items]
Sales Revenue, Goods, Net	$11,145,000	$6,312,000
Takeda [Member] | Global License Agreement [Member]
Note 11 - Collaboration and License Agreements (Details) [Line Items]
Sales Revenue, Goods, Net	$8,000

Note_11_Collaboration_and_Lice3

Note 11 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred Under the Takeda Agreement (Takeda [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015		Dec. 31, 2014
Reimbursement of Research and Development Expenses [Member] | Research and Development Revenue [Member]
Collaboration revenue:
Cash received	$1,801
Revenue recognized	2,345
Accounts receivable	1,483	[1]
Collaborative Arrangement [Member]
Collaboration revenue:
Deferred revenue, balance	845		882
Revenue recognized	37
Accounts receivable		[1]
Product Royalty Revenue [Member]
Collaboration revenue:
Cash received	18,576
Revenue recognized	15,745
Accounts receivable	-2,831	[1]
Co-Promotion Revenue [Member]
Collaboration revenue:
Cash received	1,338
Accounts receivable		[1]
[1]	Includes billed and unbilled accounts receivable.

Note_11_Collaboration_and_Lice4

Note 11 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred Under the Japan Abbott Agreement (Abbott [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Collaborative Arrangement [Member]
Collaboration revenue:
Deferred revenue, balance	$423	$453
Revenue recognized	30
Product Sales Revenue [Member]
Collaboration revenue:
Cash received	7,699
Revenue recognized	11,120
Accounts receivable	3,136
Foreign currency effects	$285

Note_12_Stock_Option_Plans_Det

Note 12 - Stock Option Plans (Details) (USD $)	3 Months Ended	12 Months Ended	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Note 12 - Stock Option Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$14.49	$7.68
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$12,000,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	11,000
Common Class A [Member] | 2006 Employee Stock Purchase Plan [Member]
Note 12 - Stock Option Plans (Details) [Line Items]
Stock Issued During Period, Value, Employee Stock Purchase Plan	$11,483		$5,386
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)	950		793
Employee Stock Option [Member]
Note 12 - Stock Option Plans (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 178 days

Note_12_Stock_Option_Plans_Det1

Note 12 - Stock Option Plans (Details) - Stock Option Activity (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
2001 Incentive Plan [Member]
Note 12 - Stock Option Plans (Details) - Stock Option Activity [Line Items]
Options Outstanding	71,400	113,900
Options Outstanding, Weighted Average Exercise Price Per Share	$10	$10
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	1 year 32 days
Options Outstanding, Aggregate Intrinsic Value	$396,984
Options exercisable	71,400
Options exercisable, Weighted Average Exercise Price Per Share	$10
Options exercisable, Weighted Average Remaining Contractual Term (Years)	1 year 32 days
Options exercisable, Aggregate Intrinsic Value	396,984
Options exercised	-42,500
Options exercised, Weighted Average Exercise Price Per Share	$10
Non Employee Stock Plan 2001 [Member]
Note 12 - Stock Option Plans (Details) - Stock Option Activity [Line Items]
Options Outstanding		255,000
Options Outstanding, Weighted Average Exercise Price Per Share		$5.85
Options exercised	-127,500
Options exercised, Weighted Average Exercise Price Per Share	$5.85
Options expired	-127,500
Options expired, Weighted Average Exercise Price Per Share	$5.85
Stock Incentive Plan 2006 [Member]
Note 12 - Stock Option Plans (Details) - Stock Option Activity [Line Items]
Options Outstanding	4,534,377	4,021,491
Options Outstanding, Weighted Average Exercise Price Per Share	$8.54	$6.93
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 321 days
Options Outstanding, Aggregate Intrinsic Value	31,824,902
Options granted	925,200
Options granted	$14.49
Options exercisable	1,141,740
Options exercisable, Weighted Average Exercise Price Per Share	$5.84
Options exercisable, Weighted Average Remaining Contractual Term (Years)	6 years 248 days
Options exercisable, Aggregate Intrinsic Value	$11,098,403
Options exercised	-345,842
Options exercised, Weighted Average Exercise Price Per Share	$6.10
Options forfeited	-63,038
Options forfeited	$6.48
Options expired	-3,434
Options expired, Weighted Average Exercise Price Per Share	$4.17

Note_13_Pension_Expense_Detail

Note 13 - Pension Expense (Details) - Net Periodic Benefit Cost Recognized (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net Periodic Benefit Cost Recognized [Abstract]
Service cost	$47	$48
Interest cost	7	11
Expected return on assets	-10	-8
Amortization of unrecognized net loss	18	4
Net periodic pension cost	$62	$55

Note_14_Income_Taxes_Details

Note 14 - Income Taxes (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 14 - Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)	$2,807,000	$1,308,000
Liability for Uncertain Tax Positions, Noncurrent	887,000
Increase (Decrease) in Income Taxes	556,000	-5,000
State and Local Jurisdiction [Member]
Note 14 - Income Taxes (Details) [Line Items]
Increase (Decrease) in Income Taxes	45,000
Other Liabilities [Member]
Note 14 - Income Taxes (Details) [Line Items]
Liability for Uncertain Tax Positions, Noncurrent	$887,000

Note_15_Segment_Reporting_Deta

Note 15 - Segment Reporting (Details)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Number of Operating Segments	1

Note_16_Subsequent_Events_Deta

Note 16 - Subsequent Events (Details) (Subsequent Event [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	1-May-15	Apr. 22, 2015
R-Tech [Member]
Note 16 - Subsequent Events (Details) [Line Items]
Proceeds from Transfer and Termination Agreement	$2.60
Drs. Ueno and Kuno [Member] | R-Tech [Member]
Note 16 - Subsequent Events (Details) [Line Items]
Equity Method Investment, Investor Ownership Percentage		50.00%